Red Queen Therapeutics

Red Queen Therapeutics, founded in Cambridge, Massachusetts, is a clinical-stage biotechnology company dedicated to addressing current and emerging viral threats. Their core mission is to develop innovative antiviral therapies that can be rapidly deployed against pandemic and pandemic-potential viruses. Utilizing a novel plug-and-play antiviral platform based on stapled peptide decoys, they aim to provide quick and effective responses to pathogens that pose significant risks to human health.

Notable figures affiliated with Red Queen Therapeutics include leading scientists and industry experts in virology and biotechnology. The company has attracted significant investment from venture capital firms specializing in healthcare innovation. Key achievements include the development of their proprietary antiviral platform, which has shown promise in preclinical trials. Red Queen Therapeutics is making a substantial impact by advancing the field of antiviral treatment and contributing to global health security.